Cargando…

Recombinant activated factor VII (rFVIIa-NovoSeven(®)-NovoNordisk) treatment of bleeding complications in intensive care unit

Detalles Bibliográficos
Autores principales:	Bonadona, A, Pavese, P, Hamidfar, R, Pernod, G, Stouls, T, Pison, C, Letoublon, C, Barnoud, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2002
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333542/ http://dx.doi.org/10.1186/cc1583

Ejemplares similares

Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven(®)) in obstetrical haemorrhagic shock
por: Sobieszczyk, S, et al.
Publicado: (2003)

Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven(®)) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
por: Thabut, D, et al.
Publicado: (2004)

Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®))
por: Bartosh, Nicole S, et al.
Publicado: (2013)

Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
por: Aggarwal, Anita, et al.
Publicado: (2004)

Use of NovoSeven(® )in cases with massive bleeding following surgery with extracorporeal circulation
por: Dementieva, I, et al.
Publicado: (2004)

Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur
por: Miatech, Jennifer L, et al.
Publicado: (2021)

A Case of “Anaphylaxis” to NovoSeven in a Hemophiliac Patient
por: Wang, Andy, et al.
Publicado: (2023)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
por: Ng, Heng Joo, et al.
Publicado: (2006)

Experience of NovoSeven administration in management of coagulopathic bleedings after surgical interventions with extracorporeal circulation
por: Dzybinskaya, E, et al.
Publicado: (2006)

Evaluation of the role of recombinant activated factor VII (NovoSeven) as a rescue haemostatic therapy in postcardiopulmonary bypass surgical patients
por: Chen, Z, et al.
Publicado: (2007)

Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
por: Poon, Man-Chiu
Publicado: (2007)

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
por: Nicosia, Dario, et al.
Publicado: (2019)

Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven(®))
por: Viuff, D., et al.
Publicado: (2008)

Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury
por: Smith, Jason E, et al.
Publicado: (2019)

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment
por: Montacir, Othman, et al.
Publicado: (2018)

Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience
por: Shah, Nurfatin Mohd, et al.
Publicado: (2018)

Experience of NovoSeven administration in the management of severe haemorrhage following cardiac surgery of nonhaemophilic patients
por: Michalska, G, et al.
Publicado: (2007)

Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding
por: Milanov, S, et al.
Publicado: (2003)

Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use
por: Bomken, Charlotte, et al.
Publicado: (2009)

Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
por: Milošević, Danko, et al.
Publicado: (2014)

Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England
por: Spivey, MH, et al.
Publicado: (2010)

Innovating to increase access to diabetes care in Kenya: an evaluation of Novo Nordisk’s base of the pyramid project
por: Shannon, Geordan D., et al.
Publicado: (2019)

Timely ‘off-label’ use of recombinant activated factor VII (NovoSeven(®)) can help in avoiding hysterectomy in intractable obstetric bleeding complicated with disseminated intravascular coagulation: A case report and review of the literature
por: Burad, Jyoti, et al.
Publicado: (2012)

Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood
por: Haidl, Harald, et al.
Publicado: (2019)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report
por: Ma, Hongbing, et al.
Publicado: (2021)

Nordisk kärlväxtflora, omfattande Sveriges, Norges, Danmarks, Ösfennoskandias, Islands och Färöarnas kärlkryptogamer och fanerogamer.
por: Hylander, Nils, 1904-1970
Publicado: (1953)

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)
por: Rajpurkar, Madhvi, et al.
Publicado: (2019)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa)
por: Kyang, Lee S., et al.
Publicado: (2019)

Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
por: Heslet, Lars, et al.
Publicado: (2012)

Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury
por: Kim, Bobby, et al.
Publicado: (2014)

Treatment of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus Patient With Local Pulmonary Administration of Factor VIIa (rFVIIa): A Case Report
por: Alabed, Iehab B.
Publicado: (2014)

Thromboelastometry as an Ancillary Tool for Evaluation of Coagulation Status after rFVIIa Therapy in a Pregnant Woman with Severe Hypoproconvertinemia—A Case Series and Review of the Literature
por: Krzyżanowski, Arkadiusz, et al.
Publicado: (2022)

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis
por: Saiyarsarai, Parisa, et al.
Publicado: (2021)

Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
por: Ishihara, Mariko, et al.
Publicado: (2015)

Combination of Novoseven and Feiba in Hemophiliac Patients with Inhibitors
por: Malkan, Umit Yavuz, et al.
Publicado: (2018)

Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
por: Kluger, Yoram, et al.
Publicado: (2007)

A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma: a re-analysis following the exclusion of early (< 48 hours) deaths
por: Rossaint, R, et al.
Publicado: (2005)

De Novo Anti-Type VII Collagen Antibodies in Patients With Recessive Dystrophic Epidermolysis Bullosa
por: Woodley, David T., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jipcdfcma337fe7pgjmbo1ro8u